Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?

Cem Gabay¹

Affiliations

Comment

Cem Gabay. Nat Clin Pract Rheumatol. 2008 Nov.

. 2008 Nov;4(11):572-3.

doi: 10.1038/ncprheum0900. Epub 2008 Sep 9.

Cem Gabay¹

¹ Division of Rheumatology at University Hospitals of Geneva, Geneva, Switzerland. cem.gabay@hcuge.ch

No abstract available

Comment on

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Smolen JS, et al. Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5. Lancet. 2008. PMID: 18358926 Clinical Trial.
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7. Lancet. 2008. PMID: 18358927 Clinical Trial.